Cargando…

DIPG-29. A CONNECT CONSORTIUM PRECLINICAL STUDY IDENTIFIES MEK INHIBITION AND RADIATION AS POTENTIAL COMBINATION PARTNERS FOR THE ALK2 INHIBITOR TP-0184 IN ACVR1-MUTANT DMG

Somatic mutations in ACVR1, which encodes the serine/threonine kinase ALK2, are found in 20-25% of DMG-H3K27 patients. Treatment of ACVR1-mutant orthotopic xenografts with multiple chemotypes of ALK2 inhibitors (ALK2i) results in extended survival in vivo but, as single agents, these inhibitors are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rogers, Rebecca, Tsoli, Maria, Kumar, Shiva Senthil, Potente, Elisabet Fernandez, Biery, Matt, Grabovska, Yura, Mackay, Alan, Carvalho, Diana, Pereria, Rita, Burford, Anna, Sejdiu, Drenusha, Ruddle, Ruth, Gabel, Florian, Raynaud, Florence, Yadavilli, Sridevi, Mizoguchi, Sean, Subramaniam, Bavani, Kilburn, Lindsey, Hwang, Eugene, Nazarian, Javad, Vitanza, Nicholas, Ziegler, David, Drissi, Rachid, Jones, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Diffuse Intrinsic Pontine Glioma/Diffuse Midline Gliomas - DPIG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259951/ http://dx.doi.org/10.1093/neuonc/noad073.076

Ejemplares similares

DIPG-37. TRANSCRIPTIONAL, EPIGENETIC, AND IMMUNOLOGICAL FEATURES OF PAEDIATRIC-TYPE H3 K27-ALTERED DIFFUSE MIDLINE GLIOMAS ORIGINATING FROM DIFFERENT BRAIN LOCATIONS
por: Grabovska, Yura, et al.
Publicado: (2023)

DIPG-47. DISCOVERING A MOLECULAR BASIS FOR VULNERABILITY OF H3K27M-DMG TO HISTONE DEACETYLASE INHIBITORS
por: Paine, Danyelle, et al.
Publicado: (2023)

DIPG-23. THE ROLE OF FOXO3 IN DMG RESISTANCE AND RESPONSE TO THERAPIES TARGETING DMG METABOLISM
por: Petrovic, Antonela, et al.
Publicado: (2023)

DIPG-10. DELTA-24-RGDOX PROMOTES ANTITUMOR IMMUNE RESPONSE IN DMG MODELS
por: Laspidea, Virginia, et al.
Publicado: (2023)

DIPG-03. IDENTIFICATION OF NEW THERAPEUTIC TARGETS BY ARRAYED CRISPRA-BASED APPROACH TO MAP RADIORESISTANCE IN DMG
por: Fernandez, Solène, et al.
Publicado: (2023)

DIPG-07. ROBUST CGAS-STING PATHWAY MEDIATED-INDUCTION OF ANTITUMOR ADAPTIVE IMMUNE RESPONSE: A POTENTIAL FOR DMG IMMUNOTHERAPY
por: Umaru, Banlanjo, et al.
Publicado: (2023)

DIPG-32. PRECLINICAL TESTING OF THE EFFICACY AND SAFETY OF CRISPR/CAS9 GENE EDITED CAR-T CELL THERAPY FOR DIFFUSE MIDLINE GLIOMA (DMG)
por: Balakrishnan, Ilango, et al.
Publicado: (2023)

DIPG-06. PRECLINICAL EVALUATION OF A NOVEL ACVR1 INHIBITOR IN DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Kumar, Shiva Senthil, et al.
Publicado: (2023)

DIPG-43. CLINICAL AND MOLECULAR CHARACTERISTIC OF A NEW SUBTYPE OF DMG, H3K27-ALTERED WITH MAPK-ACTIVATING CO-DRIVER MUTATIONS
por: Auffret, Lucie, et al.
Publicado: (2023)

DIPG-26. CLINICAL AND GENOMIC ANALYSIS OF H3K27M-DMG LONG-TERM SURVIVORS REVEALS ENRICHMENT IN MAPK PATHWAY ALTERATIONS
por: Roberts, Holly, et al.
Publicado: (2023)

DIPG-06. Uncovering the FACTs in Diffuse Midline Glioma (DMG)
por: Holliday, Holly, et al.
Publicado: (2022)

DIPG-49. International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for DMG
por: Nazarian, Javad, et al.
Publicado: (2022)

DIPG-40. Combined pharmacological and genetic screening to identify dependencies and combinations in ACVR1-mutant diffuse midline glioma
por: Rogers, Rebecca, et al.
Publicado: (2022)

DIPG-51. ACVR1 MUTATIONS PROMOTE TUMOR GROWTH IN MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Adorno, Jennifer Ocasio, et al.
Publicado: (2020)

DIPG-20. DELINEATING MEDIATORS OF ONCOGENESIS IN FOXR2-EXPRESSING DIFFUSE MIDLINE GLIOMAS
por: Tsai, Jessica, et al.
Publicado: (2023)

DIPG-33. P16 IMMUNOHISTOCHEMICAL EXPRESSION AS A SURROGATE ASSESSMENT OF CDKN2A ALTERATION IN GLIOMAS LEADING TO PROGNOSTIC SIGNIFICANCES
por: Geyer, Lucas, et al.
Publicado: (2023)

DIPG-22. TRIPTOLIDE AS A POTENTIALLY PROMISING THERAPY FOR DIFFUSE MIDLINE GLIOMA
por: Ciani, Ludovica, et al.
Publicado: (2023)

DIPG-18. AI HUNTING FOR NEW DRUGS IN PEDIATRIC GLIOMA
por: Hashizume, Rintaro, et al.
Publicado: (2023)

DIPG-45. ELONGIN B REGULATES H3K27M CHROMATIN INCORPORATION TO PROMOTE MALIGNANCY IN DIFFUSE MIDLINE GLIOMA
por: Anastas, Jamie, et al.
Publicado: (2023)

DIPG-17. TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA USING ALLELE-SPECIFIC SIRNA TARGETING H3.3 K27M MUTANT HISTONE
por: Wentworth, Simon, et al.
Publicado: (2023)

DIPG-36. H3K27M HISTONE MUTANT GLIOMAS ARE SENSITIVE TO METHIONINE LOSS AND MAT2A INHIBITION THROUGH A NOVEL FEEDBACK MECHANISM BETWEEN AMD1 AND METTL16
por: Chilukuri, Akanksha, et al.
Publicado: (2023)

DIPG-49. A SYSTEMS BIOLOGY APPROACH TO DEFINING AND TARGETING CELL STATE-SPECIFIC MASTER REGULATOR DEPENDENCIES IN DIFFUSE MIDLINE GLIOMA
por: Fernández, Ester Calvo, et al.
Publicado: (2023)

DIPG-57. TESTING FOR SYNERGY AMONG RADIATION AND HIGHLY CLINICALLY RELEVANT CHEMOTHERAPEUTIC AGENTS IN PATIENT-DERIVED MODELS OF DIFFUSE MIDLINE GLIOMA
por: Slade, Mathew, et al.
Publicado: (2023)

DIPG-16. ACUTE VERSUS PROLONGED CONVECTION-ENHANCED DELIVERY OF ALISERTIB INTO H3 K27M-MUTANT MODELS OF DIFFUSE MIDLINE GLIOMA
por: Rechberger, Julian S, et al.
Publicado: (2023)

DIPG-24. BRD4 INHIBITION AS A RADIOSENSITIZER THROUGH BLOCKING DNA REPAIR FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA
por: Watanabe, Jun, et al.
Publicado: (2023)

DIPG-54. UPDATED FINDINGS FROM THE PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY-DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
por: Lazow, Margot, et al.
Publicado: (2023)

DIPG-04. TUMOR CELL-INTRINSIC TIM-3 PROMOTES DIFFUSE INTRINSIC PONTINE GLIOMA TUMORIGENESIS
por: Ausejo-Mauleon, Iker, et al.
Publicado: (2023)

DIPG-13. NEW IMMUNOCOMPETENT GENETICALLY-ENGINEERED MOUSE MODELS OF PEDIATRIC-TYPE DIFFUSE HIGH-GRADE GLIOMAS REVEAL MECHANISMS OF TUMOR INITIATION AND PROGRESSION
por: Tian, Ruxiao, et al.
Publicado: (2023)

DIPG-12. OUTCOMES IN PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS UTILIZING TEMOZOLOMIDE, BEVACIZUMAB, AND IRINOTECAN
por: Reel, Sarah, et al.
Publicado: (2023)

DIPG-25. MAPPING TUMOR MICROENVIRONMENT USING EMERGING TECHNOLOGIES FOR PEDIATRIC BRAIN CANCERS
por: Laternser, Sandra, et al.
Publicado: (2023)

DIPG-51. ABDOMINAL METASTASES OF DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED WITH A VENTRICULOPERITONEAL SHUNT
por: Lazow, Margot, et al.
Publicado: (2023)

DIPG-40. HYPOXIC STRESS EXPOSES EPIGENETIC TARGETS TO ENHANCE RADIOTHERAPY RESPONSE IN H3K27M-POSITIVE PEDIATRIC DIFFUSE MIDLINE GLIOMAS
por: de Freitas, Amanda Pereira, et al.
Publicado: (2023)

DIPG-30. HIF2 OVEREXPRESSION DICTATES AGGRESSIVENESS ADDITIONALLY TO TP53 MUTATIONS IN H3.3K27M PEDIATRIC HIGH-GRADE GLIOMAS THROUGH RAS-MAPK AND WNT/BCATENIN PATHWAYS
por: Fuchs, Quentin, et al.
Publicado: (2023)

DIPG-56. PEDIATRIC GLIOMAS EXHIBIT A UNIQUE LIPID METABOLIC PHENOTYPE DISTINCT FROM ADULT GBMS
por: Salinas, Jennifer, et al.
Publicado: (2023)

DIPG-01. LIN28B EXPRESSION IN DIFFUSE MIDLINE GLIOMA
por: Knowles, Truman, et al.
Publicado: (2023)

DIPG-19. BAF COMPLEX PERTURBATION AS A NOVEL THERAPEUTIC OPPORTUNITY IN H3K27M PEDIATRIC GLIOMA
por: Panditharatna, Eshini, et al.
Publicado: (2023)

DIPG-35. IDENTIFYING DRIVER-SPECIFIC VULNERABILITIES IN PAEDIATRIC HIGH GRADE GLIOMA SUBTYPES
por: De Cola, Antonella, et al.
Publicado: (2023)

DIPG-53. LSD1 DEGRADATION SYNERGIZES WITH HDAC INHIBITION IN PEDIATRIC H3K27M DIFFUSE MIDLINE GLIOMA
por: Haase, Rebecca, et al.
Publicado: (2023)

DIPG-46. TARGETING THE METABOLIC ERK5-PFKFB3 AXIS IN PEDIATRIC DIFFUSE MIDLINE GLIOMA
por: Casillo, Stephanie, et al.
Publicado: (2023)

DIPG-50. INSIGHTS INTO TUMORIGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMA-ONCOHISTONE AND SIGNALING
por: Sun, Ye, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iq1n8g9uuicv6fdpd1vs5msujm